Arcutis Biotherapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
/ 
Frequently asked questions
To buy Arcutis Biotherapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Arcutis Biotherapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Arcutis Biotherapeutics Inc is ARQT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Arcutis Biotherapeutics Inc has its primary listing on NASDAQ. You can trade Arcutis Biotherapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Arcutis Biotherapeutics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Arcutis Biotherapeutics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Arcutis Biotherapeutics Inc.